Investor Alert - TRTC Revenues Stock-Price !! INVESTOR

New Post Public Reply Private Reply Replies (0) Message Board
cb11
Investor Alert - TRTC Revenues Stock-Price !!

INVESTOR ALARM ( Ver. Sept. 19th )



Bio·Vegetable & Marijuana-Hemp & Green Tech - TRTC Terra Tech Corp. - USA

( Also Medical Field )



This as attempt for by mutual consent and systematical manner

All Here once to be Agree on same Revenues or Stock- Price

Estimate numbers, because everybody just coming- up with

something different is only causing confusions and really

nothing for the GOOD we need to Relay On !





1. Up-Front lets be Agree on the Stock EPS- Ratios & Earning Definition :

- Blue- Chips have an EPS- Ratio of 10 - 20x , OK !

- None Blue- Chips have an EPS- Ratio of 30 - 60x , OK !

- TRTC as No Blue- Chip to apply middle EPS- Ration of 45x !

- TRTC Stocks instead as Issued & Outstanding 88 Mn take 100 Mn !

( OTC Markets Registered Free- Floating Stocks of 48 Mn, same as 2012 )

- Revenue is Not Earning and Earning is the Margin Not Net- Income

and Net- Income Is after Deductions of Any Expenses from Earning

and before of Any Taxes !





2. For Annual Revenues & Earning to calculate we have TRTC Information’s as :



- 5-Acre Production Plant Revenue $ 10 Mn - we apply 9 Mn by Margin 40 % !

( This also as model to sell High- Tech Companies to US Farming Industry. )



- Contracts with NB Plants of 100% & GroRite of 50% From Its Productions !

NB & GroRite Contracts grant TRTC a Royalty of 10% from its Revenues,

the complain send TRTC to increase this to at least 20% since any Agency

Royalty Standards are between 30 - 60% depending on Items- Price Range.

Wondering when the Vande Vredes will be more reasonable to allow the

Royalty of 20%, but resulting we now need to calculate by 10% only.

From NB Plants is known Revenues $ 6 Mn and GroRite $ 4 Mn, by the

Contracts % Resulting to $ 8 Mn, but we take $ 7 Mn to calculate !



- We have now the Starting Q2 of 65 Days Edible Garden Corp. participation

resulting to $ 0,665 Mn, taking this for the Quarters of usually 90 Days

would result to $ 0,920 Mn, but until now we have no TRTC reply of why

its Estimate Q2 for 65 Days of $ 0,8 Mn was not achieved and therefore

it becomes difficult to use the numbers for calculations !


- Florida Project of Revenue $ 800,000 , where TRTC get a Royalty of 15%,

the complain for after the first Business- Year to increase this also to 20%

is made to TRTC, but since there is not yet any TRTC reconfirmation we

need to calculate this by the Royalty of 15% !



- For the Hydroponic Equipments & Accessories & Companies Sales

we have not any reliable Estimate Numbers and need to wait until

the next Version of Investors Presentation.

Therefore at the moment we cannot consider this !



- For TRTC’s Electricity Management Matter we have also No Numbers

until now and therefore cannot consider this !



This Above Points 1. and 2. As Calculation Basis !!





According to Above and to make it a little more simple,

the Calculation Estimates of Revenue, Earnings and

Stock- Price only as from 2014 :



- New 5-Acre Production Plant, Revenue $ 9 Mn, Earning $ 3,6 Mn !



- NB Plants & GroRite Contracts, Revenue $ 7 Mn, Earning $ 0,7 Mn !



- Florida Project, Revenue $ 0,8 Mn, Earning $ 0,12 Mn !

( Here Without New Such Projects TRTC Announced For US Wide ! )



- Hydroponic Equipments & Accessories & Complete Companies Sales also

under Contracts for Edible Garden Products as in Florida, here not considered !



- The TRTC’s Electricity Management Matter, here not considered !



( Here Without Any MJ or Hemp Growing Projects Soon Possible ! )



As Resulting :

2014 Revenue Estimate = $ 16,8 Mn

2014 Earning Estimate = $ 4,42 Mn



TRTC Stock- Price = $ 1,99 at for example 100 Mn Stocks by EPS- Ratio 45x !!

This within the first 6 Months of 2014, depending on TRTC Progress

Information’s and the resulting Investors Reactions !!



At during 2012 until Q1 2013, the Monthly Money Net- Loss

was at $ 0,5 Mn and this now by 50% Less has improved !.

At Same Rate TRTC Will Be Writing Black- Profit Numbers

Already As From Within November 2013 !!


3. If TRTC by the US Fed. would be allowed to grow MJ or TRTC does

Grow the Gene Manipulated CBD Hemp with ZERO THC as already by

the US Senate as Industrial Agricultural Product Is US Wide Legalized,

it compare the Bio·Vegetable & Herbs could provide a 7 - 10x Higher

Profit- Margin resulting the Stock- Price of $ 1,99 to increase 6 - 8x !!



To use possibly Morphine- Based Medication with Huge- Side- Effects only

for Last Days of Life, because CBD can replace over 90 % of Morphine

Pain- Therapy Applications, beside its potential to reduce Cancer, Etc. !

For TRTC because there is no other same US company existing it means

also, if GW Pharmaceuticals owned by the Big Companies Consortium of

worldwide annual Revenues $ 160 Bn is deciding to have Production of

CBD Sativex also in the US as well for Latin America Markets, it could by

TRTC in US get the Gene Manipulated CBD Hemp produced Hydroponically

Free Of Very Toxic Pesticides, instead now just everything Europe Made !!



Depending on US MJ Laws, TRTC has the Big Potential to become

„King of Marijuana“ because has the capacity to produce the MMJ

in the Best Med. Bio-Quality for the complete US Demand without

Very Toxic Pesticides as by any other much smaller producers !!

This By TRTC‘s Office for MJ & CBD Marketing In Washington !

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Habitat for Humanity AZ's Unique Gala: An Overview

Updated Category News Views 56

Mark Your Calendars: A Night to Celebrate Listen up, Central Arizona, because I'm giving you the lowdown on Habitat for Humanity Central Arizona's big night out. "Blueprints & Blue Jeans" - it's the gala that's ditching the formalities for some good old-fashioned community fun, but with a seriously important mission at its heart. Mark your calendars for Friday, March 5,...

Continue Reading
Radiation Oncology Text Earns Doody's 2026 Nod

Updated Category News Views 122

Recognition in Radiation Oncology In the rapidly advancing arena of radiation oncology, staying current is no small feat. But here's a feather in the cap of one publication doing just that: Fundamentals of Radiation Oncology: Physical, Biological, and Clinical Aspects, 4th Edition. This resource has made quite the splash by snagging a spot on the 2026 Doody's Core Titles...

Continue Reading
Blue Owl Tech Faces Lawsuit Post-44% Share Dive

Updated Category News Views 59

The air's thick with tension for investors of Blue Owl Technology Finance Corp. (NYSE:OTF) as they wake up to the news of a securities class action lawsuit that's no small fry. You don’t have to look too far to see why the folks holding the bag might be steamed. We’re talking about a 44% drop in stock price since the merger with Blue Owl Technology Finance Corp....

Continue Reading
TELUS Targets Debt Reduction Amid Telecom Transformation

Updated Category News Views 99

Adjusting Strategy Amid Financial Challenges The market's a tough beast, and TELUS seems to be wrestling with it, showing both grit and foresight in its latest quarterly update. Third quarter 2026 has TELUS down on revenues with a notable net loss but don't count them out yet. Their Transformation Strategy is a gamble worth watching. Where the Numbers Stand Here's the...

Continue Reading
Havertys Dividend: A Steady Payout Tradition Continues

Updated Category News Views 87

Another Year, Another Dividend for Havertys Man, talk about a company with a rock-solid habit. Havertys Furniture Companies (NYSE: HVT) just announced its latest cash dividend, cementing a tradition that's been rolling since 1935. They're dropping $0.33 per share on the common stock and $0.31 on the Class A common stock. It's set to hit investors' pockets by December 9,...

Continue Reading
Koppers Faces Investigation: Investors Cautious Amid Probe

Updated Category News Views 128

Deep Dive: Koppers' Financial Turmoil When a company throws a financial party, you don't expect the hangover to come in the form of an investigation notice. That’s what’s brewing over at Koppers Holdings Inc., leading many seasoned investors to take a hard, scrutinizing look at the books. The latest buzz? An inquiry into whether the company gave its investors the full...

Continue Reading
Tenax Therapeutics Faces Legal Heat After Stock Plunge

Updated Category News Views 92

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 110

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
Encompass Health Faces Uncertain Future with Sea Pines

Updated Category News Views 119

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Continue Reading
Clean Energy: How COP31 Can Change the Future

Updated Category News Views 141

Global Warming: A Battle Heating Up Fast It's like trying to run uphill while carrying the baggage of outdated promises. We’ve got business bigwigs rallying at COP31, demanding the world to get serious about clean energy. If they don’t, we're looking at warming rocketing up to 2.6°C come year 2100. Who's listening though? The Call for Clean Electrification This mob,...

Continue Reading

Top 5 Most Recently Viewed Articles

Growing Demand in Pharmaceutical Excipients Market by 2031

Updated Category News Views 182

Let’s cut to the chase—the pharmaceutical excipients market is heating up. It's not just a smattering of growth here and there; we’re talking about a projected value that’s set to smash through USD 17.13 billion by 2031. That’s a juicy compound annual growth rate (CAGR) of 6.8% from 2024 to 2031 according to SkyQuest Technology. Why the Surge? What's fueling...

Continue Reading
Natural Retreats Enhances Guest Experience with Track Software

Updated Category News Views 354

Natural Retreats Elevates Guest Experience with New Tech Natural Retreats, a leader in the luxury vacation rental market, is making waves with its recent partnership with Track Hospitality Software. This collaboration marks a pivotal shift in how the company operates, ensuring that customer service reaches new heights. By adopting Track's cloud-based property management...

Continue Reading
Lower Factory Input Prices Signal Inflation Relief

Updated Category Economy Views 323

U.S. Manufacturing Sector Contracts for Third Consecutive Month June's U.S. manufacturing sector contracted for the third month running. From 48.7 in May, the Institute for Supply Management (ISM) recorded that its manufacturing PMI dropped to 48.5 in June. A PMI reading less than fifty suggests contraction. Ten percent or so of the U.S. economy is manufacturing....

Continue Reading
Investors Brace for Talen Energy's Earning Report This Week

Updated Category News Views 159

Talen Energy: Prepping for the Earnings Showdown Pencil this one in: February 26, 2026. That’s the big day when Talen Energy (NASDAQ:TLN) rolls out its quarterly earnings report. Investors are chomping at the bit, as EPS is projected to hit a solid $3.68. Get your game faces on folks, because this one could shake up sentiment across the board. The Whisperer’s Corner:...

Continue Reading
Legal Insights: Sage Therapeutics Under Investigation for Alleged Misconduct

Updated Category News Views 119

Understanding the Investigation Surrounding Sage Therapeutics The legal world is buzzing with developments concerning Sage Therapeutics, Inc. (NASDAQ: SAGE), a prominent name in the pharmaceutical industry. Recently, Faruqi & Faruqi, LLP—a respected national securities law firm—has ramped up efforts to investigate potential claims on behalf of investors interested in...

Continue Reading